JPMorgan initiated coverage of ANI Pharmaceuticals (ANIP) with an Overweight rating and $85 price target ANI is a specialty pharmaceuticals company with a “well-positioned and durable ...

The Busan International Film Festival (BIFF) is lining up Korean Cinema programmer Jung Hanseok for its new festival director role, though the selection process isn’t yet complete. The festival ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix ...

PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval of Purified ...

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript February 28, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.63, expectations were $1.41.

Christopher Mutz; Senior Vice President, Head of Rare Diseases; ANI Pharmaceuticals Inc Stephen Carey; Chief Financial Officer, Senior Vice President; ANI Pharmaceuticals Inc Good morning everyone.

ANI Pharmaceuticals shares rose Friday morning after the company reported better-than-expected results in the fourth quarter and raised its guidance for the current year. Shares traded over 10% ...

ANI Pharmaceuticals (NASDAQ:ANIP) Inc. reported impressive fourth-quarter 2024 earnings, surpassing both earnings per share (EPS) and revenue forecasts, leading to a notable stock price increase. The ...